eligibility_summary
CPG ≥6 months, severe itch (WI-NRS ≥6), ≥20 bilateral lesions on limbs/trunk, able to consent, comply, keep daily diary, WOCBP use effective contraception, negative COVID-19 test. Exclude pruritus from other causes, unilateral lesions, recent investigational drugs, prior benralizumab, hypersensitivity to excipients/biologics/vaccines, unstable disease, nonadherence, malignancy ≤5y, active liver disease, immunodeficiency/HIV, detention, pregnancy/lactation, active/suspected COVID-19.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 2 randomized, double-blind, placebo-controlled study (withdrawn for lack of financing) in chronic prurigo testing benralizumab (Fasenra), a humanized, afucosylated IgG1 monoclonal antibody (biologic immunotherapy) against IL‑5 receptor alpha (IL‑5Rα), 60 mg SC at weeks 0, 4, and 8 vs placebo. Mechanism: binds IL‑5Rα to block IL‑5 signaling and induces potent NK cell–mediated ADCC, leading to near-complete depletion of eosinophils and reduced basophil activity. Targets: IL‑5/IL‑5R pathway, IL‑5Rα‑expressing cells (eosinophils, basophils). Intended effect: suppress type 2/eosinophilic inflammation contributing to chronic itch and the itch–scratch cycle in chronic prurigo.